Al­to Neu­ro­science clos­es $45M round; Sim­cere part­ners with Con­nect; Myricx li­cens­es WuXi an­ti­body

Neu­ro­science com­pa­ny clos­es $45M round: Al­to Neu­ro­science closed an over­sub­scribed $45 mil­lion Se­ries C, led by In­Vivi­um Cap­i­tal, it an­nounced Tues­day. New in­vestors in­clud­ed Franklin Tem­ple­ton and Eli Lil­ly, and cur­rent in­vestors al­so chipped in. The drug­mak­er now has a board ob­serv­er, and In­Vivi­um’s Michael Liang joined Al­to’s board. The com­pa­ny plans to use the fund­ing to sup­port two treat­ments it’s de­vel­op­ing for ma­jor de­pres­sive dis­or­der, with four Phase II tri­als ex­pect­ed to read out by ear­ly 2025. Ear­li­er this year, Al­to raised $25 mil­lion from Al­pha Wave Ven­tures in a Se­ries B ex­ten­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER